Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770433 | 0.94 | RAF1 (0.45) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4265191 | 0.81 | L3MBTL1 (0.43) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL667203 | 0.77 | RAF1 (0.61) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4256267 | 0.74 | L3MBTL1 (0.38) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14434334 | 0.72 | RAF1 (0.45) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL101455 | 0.70 | RAF1 (0.42) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4781956 | 0.70 | RAF1 (0.42) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL668558 | 0.69 | RAF1 (0.49) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13912299 | 0.68 | HPGD (0.49) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4169623 | 0.68 | RAF1 (0.44) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-1986646-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | RAF1 4885/4885MAPK14 3288/4885MAPK13 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.